Drug
ASK-120067 clinical trials
- studies test it
- 10
- open now
- 6
- in phase 3
- 1
- first study started
- 2017
Keep track of what changes. Save the ASK-120067 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2022 | 2 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 6
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 5
Jiangsu Aosaikang Pharmaceutical Co., Ltd. (5) · Hunan Province Tumor Hospital (1) · The First Affiliated Hospital of Guangzhou Medical University (1) · Wen-zhao ZHONG (1) · Shanghai Chest Hospital (1) · Shanghai Pulmonary Hospital, Shanghai, China (1)
Often tested with
Tested in the same studies.
Aflutinib (5) · Rifampin (1) · Itraconazole (1) · Sintilimab (1) · Bevacizumab (1) · Sacituzumab tirumotecan (1)
Studies
Open first, then newest update. How each study uses ASK-120067 is read from its arms, and is right about nine times in ten.
Testing it · 10
- Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI ProgressionNot yet recruitingPhase 2Hunan Province Tumor HospitalNCT07001995Written as limertinib
- Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain MetastasesNot yet recruitingPhase 2The First Affiliated Hospital of Guangzhou Medical UniversityNCT07413952Written as Limertinib Plus Radiotherapy
- Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung CancerRecruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT07323056Written as Sacituzumab Tirumotecan and Limertinib
- Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067RecruitingPhase 1Jiangsu Aosaikang Pharmaceutical Co., Ltd.NCT05306132Written as ASK120067
- A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLCNot yet recruitingPhase 2Wen-zhao ZHONGNCT07038460Written as Limertinib+sintilimab+chemotherapy
- A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.Not yet recruitingPhase 2Shanghai Chest HospitalNCT06982924Written as Limertinib+bevacizumab
- ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLCActive, not recruitingPhase 3Jiangsu Aosaikang Pharmaceutical Co., Ltd.NCT04143607Written as ASK120067
- Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or ItraconazoleCompletedPhase 1Jiangsu Aosaikang Pharmaceutical Co., Ltd.NCT05631678Written as Rifampicin; ASK120067
- Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung CancerStatus unknownPhase 1/2Jiangsu Aosaikang Pharmaceutical Co., Ltd.NCT03502850Written as ASK120067
- Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy SubjectsCompletedPhase 1Jiangsu Aosaikang Pharmaceutical Co., Ltd.NCT04360915Written as ASK120067